Symbols / IMMX
IMMX Chart
About
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 449.59M |
| Enterprise Value | 270.24M | Income | -23.56M | Sales | — |
| Book/sh | 0.25 | Cash/sh | 0.47 | Dividend Yield | — |
| Payout | 0.00% | Employees | 18 | IPO | — |
| P/E | — | Forward P/E | -17.21 | PEG | — |
| P/S | — | P/B | 33.96 | P/C | — |
| EV/EBITDA | -11.34 | EV/Sales | — | Quick Ratio | 1.47 |
| Current Ratio | 1.53 | Debt/Eq | 13.39 | LT Debt/Eq | — |
| EPS (ttm) | -0.77 | EPS next Y | -0.49 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-07 17:00 | ROA | -66.48% |
| ROE | -182.55% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 52.96M |
| Shs Float | 24.84M | Short Float | 7.19% | Short Ratio | 3.01 |
| Short Interest | — | 52W High | 8.88 | 52W Low | 1.34 |
| Beta | 0.31 | Avg Volume | 1.07M | Volume | 1.04M |
| Target Price | $11.07 | Recom | Strong_buy | Prev Close | $8.17 |
| Price | $8.49 | Change | 3.92% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$11.07
Mean price target
2. Current target
$8.49
Latest analyst target
3. DCF / Fair value
$-2.24
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.49
Low
$7.20
High
$14.00
Mean
$11.07
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-09 | init | Mizuho | — → Outperform | $14 |
| 2025-12-09 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-09-12 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-06-04 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-02-10 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-01-06 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-10-03 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-08-19 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-07-26 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-07-09 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-07-01 | init | HC Wainwright & Co. | — → Buy | $7 |
| 2023-08-14 | reit | Roth MKM | Buy → Buy | $14 |
| 2023-02-22 | init | Roth MKM | — → Buy | $14 |
- Immix Biopharma (IMMX) sets price for upsized $100M stock and pre-funded warrant offering - Stock Titan Sun, 07 Dec 2025 08
- $IMMX stock is up 9% today. Here's what we see in our data. - Quiver Quantitative ue, 17 Feb 2026 19
- Immix Biopharma Stock Surges 70%, With A 6-Day Winning Spree - Trefis Wed, 10 Dec 2025 08
- Aug Weekly: Will IMMX stock go up in YEAR - July 2025 Closing Moves & Free Technical Confirmation Trade Alerts - baoquankhu1.vn ue, 24 Feb 2026 13
- Immix Biopharma, Inc.'s (NASDAQ:IMMX) market cap rose US$18m last week; retail investors who hold 56% profited and so did insiders - simplywall.st Fri, 05 Dec 2025 08
- Breakeven On The Horizon For Immix Biopharma, Inc. (NASDAQ:IMMX) - Yahoo Finance Fri, 13 Feb 2026 08
- Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition (IMMX) - Seeking Alpha hu, 11 Dec 2025 08
- Immix Biopharma stock climbs after FDA grants breakthrough therapy status - Investing.com Wed, 28 Jan 2026 08
- Analysts Expect Breakeven For Immix Biopharma, Inc. (NASDAQ:IMMX) Before Long - Sahm Mon, 16 Feb 2026 08
- Immix Biopharma Announces Pricing of Upsized $100 Million - GlobeNewswire Sun, 07 Dec 2025 08
- Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities - Benzinga Mon, 12 Jan 2026 08
- $IMMX stock is up 19% today. Here's what we see in our data. - Quiver Quantitative hu, 04 Dec 2025 08
- We Think Immix Biopharma (NASDAQ:IMMX) Needs To Drive Business Growth Carefully - Yahoo Finance Mon, 24 Nov 2025 08
- Immix Biopharma: I Am Surprised To Reaffirm A 'Buy' (IMMX) - Seeking Alpha hu, 06 Nov 2025 08
- Immix Biopharma Announces Closing of Upsized $100 Million - GlobeNewswire ue, 09 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 746 | 4976 | — | Purchase at price 6.67 per share. | RACHMAN ILYA M | Chief Executive Officer | — | 2025-12-10 00:00:00 | D |
| 1 | 770 | 5067 | — | Purchase at price 6.58 per share. | MORRIS GABRIEL S | Chief Financial Officer | — | 2025-12-10 00:00:00 | D |
| 2 | 156000 | 124800 | — | Conversion of Exercise of derivative security at price 0.80 per share. | MORRIS GABRIEL S | Chief Financial Officer | — | 2025-12-08 00:00:00 | I |
| 3 | 2500 | 5050 | — | Purchase at price 2.02 per share. | RACHMAN ILYA M | Chief Executive Officer | — | 2025-09-17 00:00:00 | D |
| 4 | 2600 | 5122 | — | Purchase at price 1.97 per share. | MORRIS GABRIEL S | Chief Financial Officer | — | 2025-09-16 00:00:00 | D |
| 5 | 2178 | 4999 | — | Purchase at price 2.30 per share. | RACHMAN ILYA M | Chief Executive Officer | — | 2025-06-18 00:00:00 | D |
| 6 | 2225 | 5071 | — | Purchase at price 2.28 per share. | MORRIS GABRIEL S | Chief Financial Officer | — | 2025-06-18 00:00:00 | D |
| 7 | 47700 | 104358 | — | Purchase at price 2.17 - 2.19 per share. | HSU JASON | Director | — | 2024-12-23 00:00:00 | D |
| 8 | 23100 | 51623 | — | Purchase at price 2.23 - 2.25 per share. | HSU JASON | Director | — | 2024-08-22 00:00:00 | D |
| 9 | 10000 | 18600 | — | Purchase at price 1.86 per share. | NG CAREY | Director | — | 2024-08-16 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | -6.17M |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -22.56M | -16.14M | -8.22M | -1.35M |
| TotalUnusualItems | 0.00 | -22.85M | ||
| TotalUnusualItemsExcludingGoodwill | 0.00 | -22.85M | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -21.61M | -15.43M | -8.23M | -24.38M |
| ReconciledDepreciation | 115.39K | 5.47K | 2.13K | 2.47K |
| EBITDA | -22.56M | -16.14M | -8.22M | -24.20M |
| EBIT | -22.67M | -16.14M | -8.22M | -24.20M |
| NetInterestIncome | 1.02M | 572.01K | -497.00 | -179.85K |
| InterestExpense | 0.00 | 497.00 | 179.85K | |
| InterestIncome | 1.02M | 572.01K | 0.00 | |
| NormalizedIncome | -21.61M | -15.43M | -8.23M | -7.71M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -21.61M | -15.43M | -8.23M | -24.38M |
| TotalExpenses | 22.67M | 16.14M | 8.22M | 1.35M |
| TotalOperatingIncomeAsReported | -22.67M | -16.14M | -8.22M | -1.35M |
| DilutedAverageShares | 28.29M | 17.34M | 13.89M | 3.67M |
| BasicAverageShares | 28.29M | 17.34M | 13.89M | 3.67M |
| DilutedEPS | -0.76 | -0.89 | -0.59 | -6.64 |
| BasicEPS | -0.76 | -0.89 | -0.59 | -6.64 |
| DilutedNIAvailtoComStockholders | -21.61M | -15.43M | -8.23M | -24.38M |
| NetIncomeCommonStockholders | -21.61M | -15.43M | -8.23M | -24.38M |
| NetIncome | -21.61M | -15.43M | -8.23M | -24.38M |
| MinorityInterests | 84.99K | 169.47K | 0.00 | |
| NetIncomeIncludingNoncontrollingInterests | -21.70M | -15.60M | -8.23M | -24.38M |
| NetIncomeContinuousOperations | -21.70M | -15.60M | -8.23M | -24.38M |
| TaxProvision | 41.04K | 26.41K | 10.27K | 6.01K |
| PretaxIncome | -21.66M | -15.57M | -8.22M | -24.38M |
| OtherIncomeExpense | -22.85M | |||
| SpecialIncomeCharges | 0.00 | -86.17K | ||
| OtherSpecialCharges | 86.17K | |||
| GainOnSaleOfSecurity | -22.76M | |||
| NetNonOperatingInterestIncomeExpense | 1.02M | 572.01K | -497.00 | -179.85K |
| InterestExpenseNonOperating | 0.00 | 497.00 | 179.85K | |
| InterestIncomeNonOperating | 1.02M | 572.01K | 0.00 | |
| OperatingIncome | -22.67M | -16.14M | -8.22M | -1.35M |
| OperatingExpense | 22.67M | 16.14M | 8.22M | 1.35M |
| ResearchAndDevelopment | 11.29M | 8.74M | 4.20M | 126.53K |
| SellingGeneralAndAdministration | 11.38M | 7.41M | 4.02M | 1.23M |
| GeneralAndAdministrativeExpense | 11.38M | 7.41M | 4.02M | 1.23M |
| OtherGandA | 11.38M | 7.41M | 4.02M | 1.23M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | |
|---|---|---|---|---|
| TreasurySharesNumber | 72.36K | 72.36K | 72.36K | |
| OrdinarySharesNumber | 27.54M | 19.92M | 13.89M | 13.23M |
| ShareIssued | 27.61M | 19.99M | 13.96M | 13.23M |
| TotalDebt | 1.07M | 0.00 | 50.00K | |
| TangibleBookValue | 13.25M | 16.41M | 13.16M | 17.99M |
| InvestedCapital | 13.25M | 16.41M | 13.16M | 18.04M |
| WorkingCapital | 11.51M | 16.07M | 13.62M | 17.98M |
| NetTangibleAssets | 13.25M | 16.41M | 13.16M | 17.99M |
| CapitalLeaseObligations | 1.07M | 0.00 | ||
| CommonStockEquity | 13.25M | 16.41M | 13.16M | 17.99M |
| TotalCapitalization | 13.25M | 16.41M | 13.16M | 17.99M |
| TotalEquityGrossMinorityInterest | 13.25M | 16.20M | 13.16M | 17.99M |
| MinorityInterest | 0.00 | -201.74K | 0.00 | |
| StockholdersEquity | 13.25M | 16.41M | 13.16M | 17.99M |
| GainsLossesNotAffectingRetainedEarnings | -1.06K | 134.67K | 87.02K | 125.41K |
| OtherEquityAdjustments | -1.06K | 134.67K | 87.02K | 125.41K |
| TreasuryStock | 99.96K | 99.96K | 99.96K | 0.00 |
| RetainedEarnings | -75.02M | -53.41M | -37.99M | -29.76M |
| AdditionalPaidInCapital | 88.37M | 69.78M | 51.16M | 47.62M |
| CapitalStock | 2.76K | 2.00K | 1.40K | 1.32K |
| CommonStock | 2.76K | 2.00K | 1.40K | 1.32K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 9.70M | 3.72M | 1.75M | 202.04K |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.01M | 0.00 | 475.00K | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 1.01M | 0.00 | ||
| LongTermCapitalLeaseObligation | 1.01M | 0.00 | ||
| LongTermProvisions | 475.00K | |||
| CurrentLiabilities | 8.69M | 3.72M | 1.27M | 202.04K |
| CurrentDebtAndCapitalLeaseObligation | 65.22K | 50.00K | ||
| CurrentCapitalLeaseObligation | 65.22K | 0.00 | ||
| CurrentDebt | 50.00K | |||
| CurrentNotesPayable | 0.00 | 50.00K | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 658.16K | 577.85K | ||
| PayablesAndAccruedExpenses | 7.96M | 3.14M | 1.27M | 152.04K |
| CurrentAccruedExpenses | 2.58M | 1.71M | 1.13M | 9.10K |
| InterestPayable | 0.00 | 9.10K | ||
| Payables | 5.39M | 1.43M | 143.07K | 142.94K |
| AccountsPayable | 5.39M | 1.43M | 143.07K | 142.94K |
| TotalAssets | 22.95M | 19.93M | 14.91M | 18.19M |
| TotalNonCurrentAssets | 2.75M | 137.41K | 10.28K | 5.70K |
| OtherNonCurrentAssets | 20.42K | 6.72K | ||
| NonCurrentDeferredAssets | 0.00 | 87.23K | 6.72K | |
| NetPPE | 2.73M | 50.18K | 3.56K | 5.70K |
| AccumulatedDepreciation | -47.26K | -14.31K | ||
| GrossPPE | 2.78M | 64.50K | 3.56K | 5.70K |
| ConstructionInProgress | 938.77K | 0.00 | ||
| OtherProperties | 844.74K | 60.60K | 3.56K | 5.70K |
| MachineryFurnitureEquipment | 3.90K | 3.90K | ||
| BuildingsAndImprovements | 989.47K | 0.00 | ||
| Properties | 0.00 | 0.00 | ||
| CurrentAssets | 20.20M | 19.79M | 14.90M | 18.19M |
| OtherCurrentAssets | 32.27K | 44.58K | 78.07K | 516.19K |
| PrepaidAssets | 509.24K | 1.06M | 1.13M | 516.19K |
| Receivables | 1.97M | 1.17M | 255.71K | 25.72K |
| TaxesReceivable | 1.97M | 1.17M | 255.71K | 25.72K |
| CashCashEquivalentsAndShortTermInvestments | 17.68M | 17.51M | 13.44M | 17.64M |
| CashAndCashEquivalents | 17.68M | 17.51M | 13.44M | 17.64M |
| CashFinancial | 17.51M | 13.44M | 17.64M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -15.77M | -11.42M | -7.41M | -1.59M |
| RepurchaseOfCapitalStock | 0.00 | -99.96K | 0.00 | |
| RepaymentOfDebt | 0.00 | -50.00K | 0.00 | |
| IssuanceOfDebt | 0.00 | 200.00K | ||
| IssuanceOfCapitalStock | 15.95M | 15.70M | 3.39M | 18.65M |
| CapitalExpenditure | -1.18M | -52.09K | -802.00 | |
| InterestPaidSupplementalData | 0.00 | 0.00 | 9.60K | 1.54K |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 17.68M | 17.51M | 13.44M | 17.64M |
| BeginningCashPosition | 17.51M | 13.44M | 17.64M | 391.09K |
| EffectOfExchangeRateChanges | -3.62K | 33.09K | -31.52K | -5.43K |
| ChangesInCash | 175.79K | 4.04M | -4.18M | 17.26M |
| FinancingCashFlow | 15.95M | 15.46M | 3.23M | 18.85M |
| CashFlowFromContinuingFinancingActivities | 15.95M | 15.46M | 3.23M | 18.85M |
| NetOtherFinancingCharges | -234.62K | -6.72K | ||
| ProceedsFromStockOptionExercised | 2.49K | 2.62K | 0.00 | |
| NetCommonStockIssuance | 15.95M | 15.70M | 3.29M | 18.65M |
| CommonStockPayments | 0.00 | -99.96K | 0.00 | |
| CommonStockIssuance | 15.95M | 15.70M | 3.39M | 18.65M |
| NetIssuancePaymentsOfDebt | 0.00 | -50.00K | 200.00K | |
| NetShortTermDebtIssuance | 0.00 | -50.00K | 200.00K | |
| ShortTermDebtPayments | 0.00 | -50.00K | 0.00 | |
| ShortTermDebtIssuance | 0.00 | 200.00K | ||
| NetLongTermDebtIssuance | 200.00K | |||
| LongTermDebtIssuance | 200.00K | |||
| InvestingCashFlow | -1.18M | -52.09K | 0.00 | -802.00 |
| CashFlowFromContinuingInvestingActivities | -1.18M | -52.09K | 0.00 | -802.00 |
| NetPPEPurchaseAndSale | -1.18M | -52.09K | 0.00 | -802.00 |
| PurchaseOfPPE | -1.18M | -52.09K | 0.00 | -802.00 |
| OperatingCashFlow | -14.60M | -11.37M | -7.41M | -1.59M |
| CashFlowFromContinuingOperatingActivities | -14.60M | -11.37M | -7.41M | -1.59M |
| ChangeInWorkingCapital | 3.97M | 1.65M | 195.21K | -391.04K |
| ChangeInOtherCurrentLiabilities | 2.85K | 0.00 | ||
| ChangeInOtherCurrentAssets | -20.42K | 0.00 | ||
| ChangeInPayablesAndAccruedExpense | 4.40M | 2.43M | 1.12M | 14.09K |
| ChangeInAccruedExpense | 0.00 | -9.10K | 120.15K | |
| ChangeInInterestPayable | 0.00 | -9.10K | 120.15K | |
| ChangeInPayable | 4.40M | 2.43M | 1.13M | -106.06K |
| ChangeInAccountPayable | 4.40M | 2.43M | 1.13M | -106.06K |
| ChangeInPrepaidAssets | 554.77K | 111.84K | -691.05K | -502.80K |
| ChangeInReceivables | -971.53K | -893.40K | -236.38K | 97.67K |
| OtherNonCashItems | 100.00K | 118.16K | ||
| StockBasedCompensation | 3.02M | 2.57M | 624.07K | 218.98K |
| DepreciationAmortizationDepletion | 115.39K | 5.47K | 2.13K | 2.47K |
| DepreciationAndAmortization | 115.39K | 5.47K | 2.13K | 2.47K |
| Depreciation | 115.39K | 5.47K | 2.13K | 2.47K |
| OperatingGainsLosses | 22.85M | |||
| GainLossOnInvestmentSecurities | 22.76M | |||
| NetIncomeFromContinuingOperations | -21.70M | -15.60M | -8.23M | -24.38M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for IMMX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|